The former enables DMD patients to produce dystrophins such as found in Becker patients, albeit at significantly lower levels, leading to a slowdown in disease progression, while the latter attempts to reestablish the functional integrity of the protein [11,12]. This evidence concerns the gene DMD and Duchenne muscular dystrophy.